KETAMINE BLUE CAPSULE - AN OVERVIEW

There was no solitary adverse response bringing about discontinuation that occurred in a price of >2% in CAPLYTA-dealt with patients.Concomitant usage of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone publicity [see Scientific PHARMACOLOGY], which can raise the danger of adverse reactions.Usually do not flush medications d